Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke

A. G. Dyker, K. R. Edwards, Pierre B Fayad, J. T. Hormes, K. R. Lees

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background and Purpose - Aptiganel (CNS 1102) is a selective, noncompetitive antagonist that acts on the ion channel associated with the N- methyl-D-aspartate (NMDA) receptor and is neuroprotective in experimental focal cerebral ischemia models at a plasma concentration of 10 ng/mL. In human volunteers, dose-limiting effects of aptiganel are blood pressure increases and central nervous system (CNS) excitation or depression. This study assessed the safety and tolerability of non-weight-adjusted doses of aptiganel in patients with acute ischemic stroke. Methods - This was a double-blind, randomized, placebo-controlled multicenter study in patients presenting within 24 hours of acute ischemic stroke. Ascending single intravenous bolus doses of aptiganel (3, 4.5, 6, and 7.5 mg) were assessed in 21 patients with a 3:1 active drug:placebo randomization schedule. In 15 subsequent patients, selected bolus doses were followed by constant intravenous infusion for 6 to 12 hours (6 mg plus 1 mg/h, n= 10; then 4.5 mg plus 0.75 mg/h, n = 15) in a 4:1 randomization schedule. Prospectively collected pharmacokinetic data guided selection of infusion rates. Neurological and functional status were recorded at entry and after 1 week, although the study was not designed to test efficacy. Results - Forty-six patients were randomized from 4 centers (3 in the United States and 1 in the United Kingdom): 36 received aptiganel HCl, and 10 were given placebo. Hypertension and CNS events were commonly reported after a bolus dose of 7.5 mg and after a 6-mg bolus followed by an infusion of 1 mg/h. The lower regimen of 4.5-mg bolus followed by infusion of 0.75 mg/h achieved plasma aptiganel concentrations of > 10 ng/mL and was well tolerated by patients but still raised systolic blood pressure by ≃30 mm Hg over baseline. Conclusions - A 4.5-mg intravenous bolus of aptiganel HCl followed by infusion of 0.75 mg/h for 12 hours is a tolerable dose that can produce plasma drug concentrations shown to be neuroprotective in animal models. However, increases in systolic blood pressure and an excess of CNS effects were both observed at this dose.

Original languageEnglish (US)
Pages (from-to)2038-2042
Number of pages5
JournalStroke
Volume30
Issue number10
DOIs
StatePublished - Jan 1 1999

Fingerprint

Stroke
Safety
Blood Pressure
Central Nervous System
Placebos
Random Allocation
Appointments and Schedules
aptiganel
N-Methyl-D-Aspartate Receptors
Brain Ischemia
Ion Channels
Intravenous Infusions
Pharmaceutical Preparations
Multicenter Studies
Volunteers
Animal Models
Pharmacokinetics
Hypertension

Keywords

  • Aptiganel
  • Glutamate antagonists
  • NMDA antagonists
  • Neuroprotection
  • Stroke, acute

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this

Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke. / Dyker, A. G.; Edwards, K. R.; Fayad, Pierre B; Hormes, J. T.; Lees, K. R.

In: Stroke, Vol. 30, No. 10, 01.01.1999, p. 2038-2042.

Research output: Contribution to journalArticle

Dyker, A. G. ; Edwards, K. R. ; Fayad, Pierre B ; Hormes, J. T. ; Lees, K. R. / Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke. In: Stroke. 1999 ; Vol. 30, No. 10. pp. 2038-2042.
@article{4900b5c5d9564896a6724cedd1ee12fa,
title = "Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke",
abstract = "Background and Purpose - Aptiganel (CNS 1102) is a selective, noncompetitive antagonist that acts on the ion channel associated with the N- methyl-D-aspartate (NMDA) receptor and is neuroprotective in experimental focal cerebral ischemia models at a plasma concentration of 10 ng/mL. In human volunteers, dose-limiting effects of aptiganel are blood pressure increases and central nervous system (CNS) excitation or depression. This study assessed the safety and tolerability of non-weight-adjusted doses of aptiganel in patients with acute ischemic stroke. Methods - This was a double-blind, randomized, placebo-controlled multicenter study in patients presenting within 24 hours of acute ischemic stroke. Ascending single intravenous bolus doses of aptiganel (3, 4.5, 6, and 7.5 mg) were assessed in 21 patients with a 3:1 active drug:placebo randomization schedule. In 15 subsequent patients, selected bolus doses were followed by constant intravenous infusion for 6 to 12 hours (6 mg plus 1 mg/h, n= 10; then 4.5 mg plus 0.75 mg/h, n = 15) in a 4:1 randomization schedule. Prospectively collected pharmacokinetic data guided selection of infusion rates. Neurological and functional status were recorded at entry and after 1 week, although the study was not designed to test efficacy. Results - Forty-six patients were randomized from 4 centers (3 in the United States and 1 in the United Kingdom): 36 received aptiganel HCl, and 10 were given placebo. Hypertension and CNS events were commonly reported after a bolus dose of 7.5 mg and after a 6-mg bolus followed by an infusion of 1 mg/h. The lower regimen of 4.5-mg bolus followed by infusion of 0.75 mg/h achieved plasma aptiganel concentrations of > 10 ng/mL and was well tolerated by patients but still raised systolic blood pressure by ≃30 mm Hg over baseline. Conclusions - A 4.5-mg intravenous bolus of aptiganel HCl followed by infusion of 0.75 mg/h for 12 hours is a tolerable dose that can produce plasma drug concentrations shown to be neuroprotective in animal models. However, increases in systolic blood pressure and an excess of CNS effects were both observed at this dose.",
keywords = "Aptiganel, Glutamate antagonists, NMDA antagonists, Neuroprotection, Stroke, acute",
author = "Dyker, {A. G.} and Edwards, {K. R.} and Fayad, {Pierre B} and Hormes, {J. T.} and Lees, {K. R.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1161/01.STR.30.10.2038",
language = "English (US)",
volume = "30",
pages = "2038--2042",
journal = "Stroke; a journal of cerebral circulation",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke

AU - Dyker, A. G.

AU - Edwards, K. R.

AU - Fayad, Pierre B

AU - Hormes, J. T.

AU - Lees, K. R.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Background and Purpose - Aptiganel (CNS 1102) is a selective, noncompetitive antagonist that acts on the ion channel associated with the N- methyl-D-aspartate (NMDA) receptor and is neuroprotective in experimental focal cerebral ischemia models at a plasma concentration of 10 ng/mL. In human volunteers, dose-limiting effects of aptiganel are blood pressure increases and central nervous system (CNS) excitation or depression. This study assessed the safety and tolerability of non-weight-adjusted doses of aptiganel in patients with acute ischemic stroke. Methods - This was a double-blind, randomized, placebo-controlled multicenter study in patients presenting within 24 hours of acute ischemic stroke. Ascending single intravenous bolus doses of aptiganel (3, 4.5, 6, and 7.5 mg) were assessed in 21 patients with a 3:1 active drug:placebo randomization schedule. In 15 subsequent patients, selected bolus doses were followed by constant intravenous infusion for 6 to 12 hours (6 mg plus 1 mg/h, n= 10; then 4.5 mg plus 0.75 mg/h, n = 15) in a 4:1 randomization schedule. Prospectively collected pharmacokinetic data guided selection of infusion rates. Neurological and functional status were recorded at entry and after 1 week, although the study was not designed to test efficacy. Results - Forty-six patients were randomized from 4 centers (3 in the United States and 1 in the United Kingdom): 36 received aptiganel HCl, and 10 were given placebo. Hypertension and CNS events were commonly reported after a bolus dose of 7.5 mg and after a 6-mg bolus followed by an infusion of 1 mg/h. The lower regimen of 4.5-mg bolus followed by infusion of 0.75 mg/h achieved plasma aptiganel concentrations of > 10 ng/mL and was well tolerated by patients but still raised systolic blood pressure by ≃30 mm Hg over baseline. Conclusions - A 4.5-mg intravenous bolus of aptiganel HCl followed by infusion of 0.75 mg/h for 12 hours is a tolerable dose that can produce plasma drug concentrations shown to be neuroprotective in animal models. However, increases in systolic blood pressure and an excess of CNS effects were both observed at this dose.

AB - Background and Purpose - Aptiganel (CNS 1102) is a selective, noncompetitive antagonist that acts on the ion channel associated with the N- methyl-D-aspartate (NMDA) receptor and is neuroprotective in experimental focal cerebral ischemia models at a plasma concentration of 10 ng/mL. In human volunteers, dose-limiting effects of aptiganel are blood pressure increases and central nervous system (CNS) excitation or depression. This study assessed the safety and tolerability of non-weight-adjusted doses of aptiganel in patients with acute ischemic stroke. Methods - This was a double-blind, randomized, placebo-controlled multicenter study in patients presenting within 24 hours of acute ischemic stroke. Ascending single intravenous bolus doses of aptiganel (3, 4.5, 6, and 7.5 mg) were assessed in 21 patients with a 3:1 active drug:placebo randomization schedule. In 15 subsequent patients, selected bolus doses were followed by constant intravenous infusion for 6 to 12 hours (6 mg plus 1 mg/h, n= 10; then 4.5 mg plus 0.75 mg/h, n = 15) in a 4:1 randomization schedule. Prospectively collected pharmacokinetic data guided selection of infusion rates. Neurological and functional status were recorded at entry and after 1 week, although the study was not designed to test efficacy. Results - Forty-six patients were randomized from 4 centers (3 in the United States and 1 in the United Kingdom): 36 received aptiganel HCl, and 10 were given placebo. Hypertension and CNS events were commonly reported after a bolus dose of 7.5 mg and after a 6-mg bolus followed by an infusion of 1 mg/h. The lower regimen of 4.5-mg bolus followed by infusion of 0.75 mg/h achieved plasma aptiganel concentrations of > 10 ng/mL and was well tolerated by patients but still raised systolic blood pressure by ≃30 mm Hg over baseline. Conclusions - A 4.5-mg intravenous bolus of aptiganel HCl followed by infusion of 0.75 mg/h for 12 hours is a tolerable dose that can produce plasma drug concentrations shown to be neuroprotective in animal models. However, increases in systolic blood pressure and an excess of CNS effects were both observed at this dose.

KW - Aptiganel

KW - Glutamate antagonists

KW - NMDA antagonists

KW - Neuroprotection

KW - Stroke, acute

UR - http://www.scopus.com/inward/record.url?scp=0032824132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032824132&partnerID=8YFLogxK

U2 - 10.1161/01.STR.30.10.2038

DO - 10.1161/01.STR.30.10.2038

M3 - Article

VL - 30

SP - 2038

EP - 2042

JO - Stroke; a journal of cerebral circulation

JF - Stroke; a journal of cerebral circulation

SN - 0039-2499

IS - 10

ER -